Status:
TERMINATED
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
Lead Sponsor:
Rabin Medical Center
Conditions:
COVID 19
Coronavirus
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The coronavirus disease 2019 (COVID-19) is an emerging pandemic in 2020 caused by a novel coronavirus named SARS-CoV2. Diabetes confers a significant additional risk for COVID-19 patients. Dipeptidyl ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- History of or type 2 diabetes mellitus or a diagnosis of type 2 diabetes during hospitalization.
- Confirmation of infection with SARS-CoV-2 by PCR testing.
- Patients within 10 days from symptom onset or patients within 48 hours after laboratory diagnosis (SARS-CoV-2 PCR).
Exclusion
- WHO COVID-19 Ordinal Scale for Clinical Improvement ≥ 6.
- Respiratory failure requiring mechanical ventilation prior to randomization.
- Use of vasopressor or inotropic medications prior to randomization.
- Intolerance/hypersensitivity to dipeptidyl peptidase-4 inhibitors.
- Patients expected to require intensive care unit admission or immediate surgical intervention.
- Participation in another trial assessing any treatment for COVID-19.
- Current treatment with a DPP-4 inhibitor.
- Pregnancy.
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 4 2021
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT04371978
Start Date
October 1 2020
End Date
May 4 2021
Last Update
June 2 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Shamir Medical Center
Be’er Ya‘aqov, Israel
2
Rabin Medical Center, Beilinson Campus
Petah Tikva, Israel
3
Rabin Medical Center, Hasharon Campus
Petah Tikva, Israel